In vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-β-cyclodextrin

被引:18
作者
Nie, Shufang [1 ]
Fan, Xiaowen [1 ]
Peng, Ying [1 ]
Yang, Xingang [1 ]
Wang, Chao [1 ]
Pan, Weisan [1 ]
机构
[1] Shenyang Pharmaceut Univ, Dept Pharmaceut, Shenyang 110016, Peoples R China
关键词
vinpocetine; hydroxypropyl-beta-cyclodextrin; inclusion complexes; citric acid; improving dissolution rate; bioavailability;
D O I
10.1007/BF02993968
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The purpose of this study was to evaluate complexes of vinpocetine (VIN), a poorly water-soluble base type drug, with hydroxypropyl-beta-cyclodextrin (HP-beta-CD) in aqueous environment and in solid state, with or without citric acid (CA) as an acidifier of the complexation medium. The apparent stability constant (K-c) calculated by phase solubility was 282 M-1 and the complexation in solution was structurally characterized by H-1-NMR which showed VIN was likely to fit into the cyclodextrin cavity with its phenyl ring and ethyl ester bond. Solid complexes of VIN and HP-beta-CD were prepared by kneading (KE), co-evaporating (CE) and freeze-drying (FD) methods. Physical mixtures were prepared for comparison. The study in the solid state included the differential scanning calorimetry (DSC), X-ray diffractometry (XRD) and infrared absorption spectroscopy (IR). From these analyses, CE and FD products were found in amorphous state, allowing to the conclusion of strong evidences of inclusion complex formation. However, the dissolution test showed that only VIN/HP-beta-CD+CA complexes by CE and FD method could provide satisfying dissolution behavior (rapid, complete and lasting) when compared to that of VIN/HP-beta-CD complexes. Interestingly, the addition of CA in inclusion complexes could significantly decrease the amount of HP-beta-CD needed to solubilize the same amount of VIN and thereby reducing the formulation bulk. Furthermore, in-vivo study revealed that the bioavailability of VIN after oral administration to rabbits (n=6) was significantly improved by VIN/HP-beta-CD+CA inclusion complex.
引用
收藏
页码:991 / 1001
页数:11
相关论文
共 19 条
[1]  
Amato ME, 1998, MAGN RESON CHEM, V36, P693
[2]   CYCLODEXTRINS IN THE PHARMACEUTICAL FIELD [J].
BEKERS, O ;
UIJTENDAAL, EV ;
BEIJNEN, JH ;
BULT, A ;
UNDERBERG, WJM .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1991, 17 (11) :1503-1549
[3]  
Brewster M.E., 1991, NEW TRENDS CYCLODEXT, P313
[4]  
CSANDA E, 1988, Drug Development Research, V14, P185, DOI 10.1002/ddr.430140304
[5]   A STUDY OF THE INCLUSION COMPLEX OF NAPROXEN WITH BETA-CYCLODEXTRIN [J].
ERDEN, N ;
CELEBI, N .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1988, 48 (1-3) :83-89
[6]   INCLUSION COMPLEXATION OF GLIBENCLAMIDE WITH 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN IN SOLUTION AND IN SOLID-STATE [J].
ESCLUSADIAZ, MT ;
TORRESLABANDEIRA, JJ ;
KATA, M ;
VILAJATO, JL .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 1 (06) :291-296
[7]  
GRANDT R, 1989, ARZNEIMITTEL-FORSCH, V39-2, P1599
[8]   IMPROVEMENT OF THE INVITRO DISSOLUTION CHARACTERISTICS OF FAMOTIDINE BY INCLUSION IN BETA-CYCLODEXTRIN [J].
HASSAN, MA ;
SULEIMAN, MS ;
NAJIB, NM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 58 (01) :19-24
[9]  
Higuchi T., 1965, Interscience, New York, V4, P117
[10]  
KATA M, 1982, PHARMAZIE, V37, P386